Royal Bank of Canada reissued their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a report published on Sunday morning, AnalystRatings.com reports. Royal Bank of Canada currently has a $27.00 target price on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on PRQR. ValuEngine downgraded shares of ProQR Therapeutics from a buy rating to a hold rating in a report on Thursday, August 8th. Zacks Investment Research raised shares of ProQR Therapeutics from a sell rating to a hold rating in a report on Wednesday, July 10th. Finally, BidaskClub downgraded shares of ProQR Therapeutics from a sell rating to a strong sell rating in a report on Wednesday, July 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. ProQR Therapeutics has an average rating of Buy and a consensus target price of $28.43.

Shares of NASDAQ:PRQR opened at $8.94 on Friday. The firm has a fifty day moving average price of $8.82. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.51 and a current ratio of 9.51. ProQR Therapeutics has a one year low of $7.20 and a one year high of $24.00. The company has a market cap of $343.61 million, a P/E ratio of -6.93 and a beta of 0.11.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of ProQR Therapeutics in the 4th quarter valued at $11,064,000. Northern Trust Corp bought a new position in shares of ProQR Therapeutics in the 4th quarter valued at $666,000. Geode Capital Management LLC lifted its stake in shares of ProQR Therapeutics by 14.1% in the 4th quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 2,375 shares during the last quarter. Barclays PLC bought a new position in shares of ProQR Therapeutics in the 4th quarter valued at $51,000. Finally, Squarepoint Ops LLC bought a new position in shares of ProQR Therapeutics in the 4th quarter valued at $169,000. 60.87% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Featured Article: What is a Futures Contract?

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.